Latest news and press releases about Calidi Biotherapeutics, Inc. (CLDI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents.
Price
| Price | $1.17 |
| Market Cap | $1M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.53 |
| EV / EBITDA | 0.09 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -372.86% |
| Return on Invested Capital | -347.09% |
| Return on Assets | -242.55% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CANF · CMND · CNSP · KZIA · QLGN · SILO · SNGX
Explore sector: Healthcare · Biotechnology
More sections of CLDI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks